Louis Kavoussi, MD, MBA, Director of teleintervention at Northwell. He is a world-renowned urologic surgeon who brings more than 30 years of specialized expertise in minimally invasive urological surgery. His area of focus includes treating a wide range of urologic diseases, including kidney obstructions, renal stones and urologic cancer. At the forefront of innovation, Dr. Kavoussi pioneered several new surgical techniques, including the first minimally invasive approaches to kidney surgery for kidney cancer and kidney donation. He was also part of the team that performed the first laparoscopic prostate removal for cancer. In 1999, Dr. Kavoussi received a Smithsonian Computerworld Permanent Collection award for his work in developing telerounding, the starting point of telehealth medicine-to facilitate physician communication with hospitalized patients. Before joining Northwell in 2005 as chair of urology, Dr. Kavoussi completed his medical degree at the State University of New York at Buffalo. He obtained his urologic training at Washington University of St. Louis and, directly following residency, was named chief of urology at the Jewish Hospital of St. Louis. In 1991, he was appointed assistant professor at Harvard School of Medicine and director of endourology at the Brigham and Women's Hospital. In 1993, he joined the faculty of Johns Hopkins University School of Medicine, where he was vice chairman of urology and named a Patrick C. Walsh Distinguished Professor. Dr. Kavoussi values a team approach to care, and often collaborates with other specialists to create personalized and comprehensive treatment plans. His patients appreciate his easygoing personality and thoughtfulness. As the Waldbaum-Gardner Distinguished Professor of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Dr. Kavoussi is passionate about training the next generation of surgeons. He has presented his work and given live surgical demonstrations at conferences around the world and has more than 500 academic publications. Dr. Kavoussi is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Reconstructive Urology Surgery.

Rohit Jain is an Oncologist and a Hematologist Oncology provider in Flushing, New York. Dr. Jain is rated as an Elite provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Urothelial Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Penectomy, and Endoscopy. Dr. Jain is currently accepting new patients.

As Senior Vice President of the Urology Service Line, Chair of theSmith Institute for Urology, and Chair of Urology at the Zucker Schoolof Medicine at Hofstra/Northwell, Samir Taneja, MD will establish hisclinical practice at Lenox Hill Hospital and Long Island Jewish MedicalCenter focused on the surgical management of prostate cancerand renal tumors. He is an expert in urologic oncology, renowned fortransforming the field of prostate cancer diagnosis and treatmentby improving methods of prostate imaging, cancer detection, anddisease localization. Having performed thousands of robotic, ablative,laparoscopic and open surgical procedures, his specific clinical focushas been in improving prostate cancer patient outcomes throughpioneering techniques for focal ablative therapy, refining surgicaltechniques for robotic prostatectomy and partial nephrectomy,devising accelerated recovery pathways for robotic prostatectomy/partial nephrectomy, and providing muti-modal surgical approachesfor patients with high risk and recurrent prostate cancer. As leader ofthe department, he will strive to ensure individualized care of urologicdisease through state-of-the-art surgical approaches and multi-disciplinary care.Prior to joining Northwell, Dr Taneja was a faculty member of NYUGrossman School of Medicine for 29-years as a tenured professorof urology, radiology, and biomedical engineering. Most recently heserved as Director of the Division of Urologic Oncology and ViceChair in the Department of Urology at NYU Langone Health, as well asGenitourinary Program Leader in the Perlmutter Cancer Center.Dr. Taneja has conducted extensive clinical research on the use ofimaging in prostate cancer and is considered a pioneer in the use ofMRI to diagnose and localize prostate cancer and the emerging field ofprostate cancer focal therapy. He has authored more than 250 articles,30 book chapters, and six textbooks and monographs on urologiccancer and surgery. He is the editor of Taneja's Complications ofUrologic Surgery: Prevention and Diagnosis, one of the most widely readtextbooks in American Urology. Dr. Taneja is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Joph Steckel is an Urologist in Lake Success, New York. Dr. Steckel is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Nephrectomy, and Reconstructive Urology Surgery.

Michael Herman is an Urologist in Rockville Centre, New York. Dr. Herman is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Obstructive Uropathy, Urinary Tract Infection in Children, UPJ Obstruction, Ureteroscopy, and Reconstructive Urology Surgery.

Alvin Goh is an Urologist in Uniondale, New York. Dr. Goh is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Bladder Cancer, Urothelial Cancer, Congenital Giant Megaureter, Cystectomy, and Nephrectomy. Dr. Goh is currently accepting new patients.

Joseph Jamal is an Urologist in Garden City, New York. Dr. Jamal is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Ureterocele, Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Nephrectomy, and Reconstructive Urology Surgery.

Kai Tsao, MD, MS, is the system chief of solid tumor oncology, medical director of the R.J. Zuckerberg Cancer Center, and medical director of the medical oncology prostate cancer program at the Northwell Cancer Institute. He specializes in cancers of the genitourinary organs and has more than a decade of clinical experience. His research focuses on the development of biomarkers and novel therapies for patients with genitourinary cancers.Dr. Tsao was inspired to become an oncologist after witnessing many close family and friends suffering from cancer. He completed medical school training at SUNY Downstate, an internal medicine residency at Long Island Jewish Medical Center, and a fellowship in hematology and medical oncology at Mount Sinai Hospital. He earned a master's degree in healthcare delivery leadership at Icahn School of Medicine at Mount Sinai and completed Lean Six Sigma training at Johns Hopkins.Prior to joining Northwell, Dr. Tsao served as medical director of the Ruttenberg Treatment Center, medical director of the medical oncology prostate cancer program, and physician leader for internal oncology collaborations at the Mount Sinai Hospital, Tisch Cancer Institute. In these roles, Dr. Tsao and his team built a cancer center that is patient centered, quality driven, scientifically innovative, and provided multi-disciplinary care to patients with cancer.For me, patient care much more than the cancer diagnosis and treatment. It is essential to address the many needs of our cancer patients: emotional well-being, social support, nutrition, physical activity, financial challenges and more. We aim to provide the best support for our patients, one at a time.Dr. Tsao is an accomplished physician-scientist who has authored more than 80 peer-reviewed publications in the field of genitourinary oncology. He serves as associate editor of Genitourinary Oncology, Frontiers in Oncology. His leadership in carrying out complex clinical trials in targeted therapies and immunotherapies positions his patients at the forefront of cutting-edge cancer research and patient-centered care.What I most enjoy every day is seeing patients under our care, despite the devastation of their cancer diagnosis, beating their cancer and living a life that was not considered a possibility years ago. Our mission at Northwell Cancer Institute is to make this a reality for every single patient. Dr. Tsao is rated as a Distinguished provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Orchiectomy, and Nephrectomy.

Sydney Yoon is a Radiologist and an Interventional Radiologist in Oceanside, New York. Dr. Yoon is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Stroke, Ascites, Pleurisy, Bone Marrow Aspiration, and Gastrostomy.

Geraldine Abbey-Mensah is an Interventional Radiologist and a Radiologist in Oceanside, New York. Dr. Abbey-Mensah is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Ascites, Pleurisy, Pleural Effusion, Bone Marrow Aspiration, and Gastrostomy.

Jean Lee is a Hematologist Oncology specialist and an Oncologist in Oceanside, New York. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Endometrial Cancer, Pseudomyxoma Peritonei, Malignant Mixed Mullerian Tumor, and Endometrial Stromal Sarcoma.

Leester Wu is a Radiologist and a Radiation Oncologist in Oceanside, New York. Dr. Wu is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Trigeminal Neuralgia, Pleuropulmonary Blastoma, Lung Cancer, and Familial Prostate Cancer.

David Li is an Interventional Radiologist and a Radiologist in Oceanside, New York. Dr. Li is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Ascites, Pleural Effusion, Pleurisy, Liver Embolization, and Gastrostomy. Dr. Li is currently accepting new patients.

Valerie Kremer is a Hematologist in Rockville Centre, New York. Dr. Kremer is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Thrombocytopenia, Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, and ALK-Positive Non-Small Cell Lung Cancer.

Mary Leung is a Hematologist and an Oncologist in Rockville Centre, New York. Dr. Leung is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). Her top areas of expertise are Anemia, Angiosarcoma, Paget Disease of the Breast, Lung Adenocarcinoma, and Bone Marrow Aspiration.

Kenneth Angelino is a Hematologist and an Oncologist in Rockville Centre, New York. Dr. Angelino is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Thrombocytopenia, Anemia, Vulvar Cancer, and Angiosarcoma.

Raymond Sultan is an Urologist in Rockville Centre, New York. Dr. Sultan is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Bilateral Hydronephrosis, Ureteroscopy, and Prostatectomy.

Eric Thall is an Urologist in Rockville Centre, New York. Dr. Thall is rated as an Experienced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Enlarged Prostate (BPH), Obstructive Uropathy, UPJ Obstruction, Ureteroscopy, and Reconstructive Urology Surgery.

Craig Warshall is a Radiologist and a Neuroradiologist in New Hyde Park, New York. Dr. Warshall is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Stroke, Cerebral Arteriovenous Malformation, Cerebellar Multiple System Atrophy, and Subarachnoid Hemorrhage.

Dr. Simon J Hall MD is a board certified urologist with Fellowship training in Urologic Oncology. His clinical interests include the diagnosis and treatment of Prostate, Bladder and Kidney cancers. He is especially interested in Active Surveillance of men with prostate cancer and men and women with incidentally found small renal masses and the creation of continent urinary reconstructions for patients who need to undergo cystectomy for Bladder cancer. Furthermore, Dr. Hall has a keen interest in treating patients with recurrent prostate cancer following definitive therapy. He believes that objective & balanced communication with the patient and family is the key to decision making and individualized care. Over the years Dr. Hall has been named as Best Doctor, both nationally and regionally, by organizations such as Castle Connolly, SuperDoctors and New York Magazine. Dr. Hall s research has focused of new therapies for prostate and bladder cancer; he has participated in numerous clinical trials, some of which generated data resulting in FDA approval of Sipleucel-T (Provenge) and enzulutamide (Xtandi). He oversees a laboratory investigating novel approaches to negating the Androgen Receptor, an important key driver of castration resistant prostate cancer. Decision making and improved methods of clinical care for patients with bladder and prostate cancer are important aspects of his research interests in collaboration with Dr. Michael Diefenbach, a behavioral scientist in the Departments of Urology & Medicine at NS-LIJ. He has authored or co-authored nearly 70 peer reviewed articles in Journals such as Journal of Urology, Urology, British Journal of Urology, Clinical Cancer Research and Science. Dr. Hall received his MD from the College of Physicians & Surgeons of Columbia University. He then completed two years of Surgery training at the Mount Sinai Medical Center followed by a four year residency in Urology at Boston University School of Medicine. This was followed by a 2 year fellowship in Urologic Oncology in the Scott Department of Urology at Baylor College of Medicine. Prior to joining the Smith Institute for Urology, he served on the faculty of Icahn School of Medicine at Mount Sinai for 18 years, holding various positions including Kyung Hyun Kim MD Chair of Urology and the Director of the Deane Prostate Health & Research Center. Dr. Hall is rated as an Advanced provider by MediFind in the treatment of Renal Cell Carcinoma (RCC). His top areas of expertise are Muscle Invasive Bladder Cancer, Prostate Cancer, Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.